Aerie shares rocket up as glaucoma combo drug scores positive data
Shares of Aerie Pharmaceuticals $AERI skyrocketed on promising data for a combination glaucoma drug that bested its own late-stage drug Rhopressa by adding a well …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
